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Abstract 
Inflammation is a significant component of neurological diseases such as multiple 
sclerosis (MS). One potential anti-inflammatory agent, rolipram, was tested for efficacy in MS; 
however, despite showing promise in early trials, the drug has been largely sidelined due to side 
effects. However, it is still of interest to elucidate the anti-inflammatory mechanisms of rolipram 
in order to identify more targeted inhibitors of inflammatory signaling. In order to achieve this 
end, we have utilized liquid chromatography-mass spectrometry-based metabolomics to 
determine metabolic pathways that are altered by rolipram treatment in human THP-1 monocytic 
cells and primary mouse microglial cultures.  Amino acids and related metabolites as well as 
steroid species were identified as being significantly dysregulated. Shotgun lipidomics showed 
upregulation of glycerophospholipids, including phosphatidylcholine and phosphatidylserine 
after rolipram treatment. Taken together, these results suggest that rolipram inhibition of cAMP 
breakdown leads to significant alterations on the metabolome of monocytic immune cells. 
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Introduction 
Rolipram is a phosphodiesterase-4 (PDE-4) inhibitor originally developed as anti-
inflammatory agent(Zhu et al., 2001). This drug acts to prevent the breakdown of 3’, 5’-cyclic 
adenosine monophosphate (cAMP). cAMP is a second messenger in a number of different 
intracellular signaling cascades induced by hormonal, neurotransmitter, and cytokine 
stimulation(Hurley et al., 1999). In line with this role, studies have shown that cAMP inhibition 
by rolipram has a potent anti-inflammatory action due to its ability to attenuate production of 
nitric oxide (NO) and other pro-inflammatory cytokines in immune cells(Yang et al., 2008). 
Microglial cells are the resident macrophages of the central nervous system and play both 
beneficial and harmful roles in neurodegenerative processes.  Microglial cells enter into an 
activated state after tissue injury and phagocytose damaged cells to promote healing(Rock et al., 
2004).  However, these cells also release pro-inflammatory mediators such as tumor necrosis 
factor alpha (TNF) and NO that may result in additional pathology after brain insults(Guadagno 
et al., 2013). Along with microglia, macrophages from the peripheral tissues also migrate into the 
damaged nervous system and these cells are an additional target for rolipram(Zhang et al. 2002).  
Initial preclinical testing of rolipram in autoimmune disorders such as multiple sclerosis 
were successful and the drug advanced to clinical trials. Unfortunately, these trials were 
discontinued when it was discovered that rolipram administration precipitated potent 
gastrointestinal side effects, namely vomiting(Robichaud, 2001).  Though early enthusiasm has 
faded, rolipram, as well as other PDE-4 inhibitors, remain of interest as potential 
immunomodulatory drugs if side effects can be overcome. Several potential modifications could 
facilitate the use of these compounds, including targeted delivery to lesions in the CNS to avoid 
the gut or pairing rolipram with another drug(Glueckert, 2015). In order to design more robust 
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inhibitors of PDE-4 with fewer side effects; it is necessary to better understand the mechanisms 
by which this class of compounds could act. 
Several in vitro cell lines share the characteristics of primary tissue microglia and 
macrophages. An immortalized monocytic line, THP-1, is easily cultured and phenotypically 
similar to tissue macrophages.  These cells respond to inflammatory mediators such as bacterial 
lipopolysaccharide and release cytokines, including interleukins 1, 6, and 8, TNF, and 
others(Chanput, 2014.).  This tissue culture model of tissue macrophages provides an 
opportunity to evaluate anti-inflammatory mechanisms induced by rolipram.  
 Untargeted metabolomic profiling is a powerful tool for interrogating the therapeutic 
actions and off-target effects of compounds (Patti et al., 2015).  Global profiling measures 
changes to the entire metabolome and this technology allows the detection of alterations in 
biologically important species such as amino acids, nucleic acids, neurotransmitters, and 
signaling molecules in response to drug administration or tissue pathology(Kaddurah-Daouk et 
al., 2008). Currently, the most popular analytical technique to measure metabolites is liquid 
chromatography-mass spectrometry (LC-MS)(Patti et al., 2015).  In this study, we applied a 
platform that combines hydrophilic chromatography-mass spectrometry (HILIC-MS) with 
shotgun lipidomics to determine changes in polar species and lipids associated with rolipram 
treatment(Han et al., 2005).   
Figure 1: Untargeted Metabolomics platform to identify drug mechanisms 
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Materials and Methods 
Chemicals 
Rolipram (>99.9%) was purchased from Enzo Biosciences (Farmingdale, NY,USA). 
Lipopolysaccharide was purchased from Sigma Aldrich (St. Louis. MO, USA). Phorbol 12-
myristate 13-acetate (PMA) was purchased from Fischer Scientific (Fair Lawn, NJ, USa). 
Phosphate buffer saline (PBS), Dulbecco’s Modification of Eagle’s Medium (DMEM), and 
penicillin-streptomycin were purchased from Corning (Manassas, VA, USA.) HPLC-grade 
water, ethanol, methanol, and acetonitrile were purchased from Fischer Scientific (Fair Lawn, 
NJ, USA.) All MTT materials, including thiazolyl blue tetrazolium bromide (MTT) were 
purchased from Sigma Aldrich (St. Louis, MO, USA.)  
Cell Culture 
The THP-1 cell line was a gift from the Paruchuri lab. These cells were cultured in 
DMEM media with 10% FBS and 1% penicillin-streptomycin and grown at 37C in 5% CO2. 
For experimental procedures, the cells were plated at approximately 1.0 x 106 cells per well in 
six well plates in a total volume of 3 mL per well for 24 hours. Cells were subsequently treated 
with 100 nM phorbol 12-myristate 13-acetate (PMA), a protein kinase C activator, for a period 
of 72 hours to induce their differentiation from a monocytic phenotype into macrophage-like 
cellls. After this period, rolipram was added to the experimental group at a concentration of 5 
μM dissolved in DMSO for an additional 24 hours.  
 Primary glial cultures were prepared from C57BL/6 mice according to a protocol 
approved by the institutional care and use committee (IACUC) at the University of Akron 
(protocol # 14-03-03). Cortices from neonatal mice were isolated and placed in in a falcon tube 
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with 5 mL of HBSS.  Tissue was minced 
and 0.1 mL DNAse I (0.2 mg/mL) was 
added to each tube, along with 0.1 mL 
trypsin (1mg/mL.)  After 15 minutes of 
incubation at 37 °C, 2 mL of media 
(DMEM +10% FBS and 1% 
Penicillin/Streptomycin) was added to 
each sample to halt trypsinization, and 
centrifuged at 100 x g for 10 min. The supernatant was discarded and 5 mL of plating media was 
added to each tube to dissociate the pellet. The sample was then run through a 40 µm diameter 
strainer and the flow-through was collected. After counting, the cells were plated at 
approximately 1x106 cells/mL in 15 mL of DMEM in a poly-D-lysine coated T75 flask. Cells 
were incubated at 5% CO2 and 37 °C for approximately ten days to reach confluency. The flasks 
were subsequently shaken on an orbital shaker under incubation at 37 °C for a period of three 
hours to allow microglia to detach from the adherent astrocytes.  The supernatant, containing the 
free-floating microglia, was separated into a 50 mL conical flask and centrifuged at 168 x g for 
10 min at 4 °C. The pellet, containing the microglia, was resuspended in DMEM. The cells were 
counted and plated at a density of 1.0 x105 cells per well in six well plates 
with 3 mL of media (DMEM) in each well, and allowed to adhere for one day.  In some 
experiments, cultures consisted of both astrocytes and microglial cells (i.e. mixed glial cultures).  
Metabolite Extraction 
Metabolites were isolated from rolipram and control-treated cells by using a modified 
Bligh-Dyer Extraction(Bligh and Dyer, 1959; Fei et al., 2014). After drug treatment, tissue 
Figure 2: Brightfield image of primary 
mouse-isolated microglia cells at 200X 
magnification. 
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culture medium was aspirated away and 180 µL HPLC grade water with 20 µL HPLC methanol 
was added to each well prior to removing cells from the bottom of the plates by scraping. 
Isolated cells were subsequently resuspended into 200 µL of cold HPLC-grade methanol. 
Samples were subjected to three rounds of freezing in liquid nitrogen, thawing, and sonication to 
lyse the cell membrane. Solvents consisting of 750 µL of 1:2(v:v) chloroform: methanol and 125 
µL chloroform were added to each sample along with 250 µL of water. Cells were then 
incubated for one hour at -20C, followed by centrifugation at 100 x g for 10 minutes at 4C in 
order to facilitate the formation of an upper aqueous phase, a lower organic phase and a protein 
disk between the two phases. Care was taken to separate both aqueous and organic phases into 
centrifuge tubes, leaving the protein disk undisturbed in the original tube. All samples were then 
dried in a CentriVap concentrator and stored at -80oC until MS analysis.  Storage varied 
according to the trial and instrument availability.  
Mass Spectrometry 
A bicinchoninic acid assay(BCA) was performed on protein pellets to normalize between 
samples.  Subsequently, samples were resuspended in 35% acetonitrile in water at a volume 
commensurate with protein concentration. A 5 µL volume was injected into the Micro200 
LC(Eksigent, Redwood, CA, USA) equipped with a hydrophilic interaction liquid 
chromatography(HILIC) column(Luna 3μ NH2 100Å, 150mm×1.0mm, Phenomenex, Torrance, 
CA, USA). Water and acetonitrile, each with 5 mM ammonium acetate, were used for mobile 
phase A and B, respectively(Taraboletti et al., 2016). The HPLC gradient ran at a flow rate of 30 
μL/ min as follows: 0 min 98% B, 1 min 95% B, 5 min 80% B, 6 min 46% B, 13 min 14.7% B, 
17 min 0% B, 17.1 min 100% B, 23 min 100% B(Taraboletti et al., 2016). 
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 Following separation, samples were injected into an AB SCIEX 5600+ TripleTOF mass 
spectrometer. The ion source nebulizer gas set to 15 psi, heater gas was set to 20 psi, and curtain 
gas  was set to 25 psi. Positive mode samples were collected with an ionspray voltage of +5000 
V and a +100 volt declusteirng potential(Taraboletti et al., 2016). A collision energy spread of 
+25-40V was used to collect fragmentation data on all candidate ions(Taraboletti et al., 2016). 
Shotgun Lipidomics 
Extracted organic phase metabolites were resuspended in a methanol:chloroform:water(v:v:v, 
45:45:10, 5 mM ammonia acetate) mixture and then placed in an LC vial. Lipid samples were 
injected at a flow rate of 10 µL/min. An MS/MSALL  method was employed for the lipid analysis 
using a scan range of 200-1,200 Da with an accumulation time of 300 ms(Simons et al., 2012). 
The method was run once in positive mode and once in negative mode(Taraboletti et al., 2016). 
MTT Assay 
An MTT assay was performed on mouse mixed glial cultures to determine the effect of 
rolipram on cell viability. Glial cells were plated at a concentration of approximately 1.0 x104 
cells per well for a period of three days to allow the cells to adhere and populate. Cells were then 
treated with  i) rolipram alone, ii) 5 M rolipram and 100 ng/mL LPS, iii) 100 ng/mL LPS, or iv) 
100 ng/mL LPS with varying concentrations of rolipram.  For the last treatment group containing 
varying concentrations of rolipram with constant LPS, rolipram was added at concentrations 
ranging from 20 µM to 40 nM. The plate was then left to incubate for an additional 24 hours 
after which 5 mg/mL MTT was added. Samples were incubated with MTT for 4 hours, lysed in 
buffer containing 4 mM HCl, 0.1% NP40 in isopropanol, and  the plate was read at 590 
nanometers with a Spectromax M2 plate-reader(Molecular Devices, Sunnyvale, CA, USA).   
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Bioinfomatics  
Peak picking and retention time alignment was performed by using Markerview 
software(AB SCIEX). After importing data from wiff files generated from the mass 
spectrometer, PCA analysis was performed to identify differences between groups. Elements 
software(Proteome Software, Inc) was used to compare vehicle-treated versus rolipram-treated 
cells, identify metabolites based on MS and MS/MS data, and determine features that were 
significantly different between the two.  Identification was based on matching MS and MS/MS 
data to entries in the publicly-available metabolite databases, the Human Metabolome 
Database(HMDB, http://www.hmdb.ca/), Metlin(https://metlin.scripps.edu/), and the National 
Institute for Standards and 
Technology(nist.gov). 
Differences in the relative 
levels of metabolites were 
determined based an adjusted 
p value < 0.05 and Log2 fold 
change of greater than 2 or 
less than -2.  Pathway 
analysis was performed by 
using the online software 
package, 
Figure 3: Determination of the viability of mixed glial cells treated 
with LPS.  Mixed glial cells were treated with LPS at increasing 
concentrations and viability was determined with MTT assay. N=3 
cell cultures for each concentration. Kruskal-Wallis(One Way 
ANOVA) analysis demonstrated the difference in viability to be 
significant between the treatment groups and the zero LPS 
concentration treatment. 
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MetaboAnalyst(www.metaboanalyst.ca). Lipidomic data was analyzed with LipidView software 
(AB Sciex). 
Results 
This project focused on 
studying the effect of the 
anti-inflammatory agent, 
rolipram, on the global 
metabolic responses of 
peripheral macrophages 
and CNS resident 
microglial cells.  We first 
wanted confirm that our 
drug concentrations were 
within a sufficient range 
and so we performed an 
MTT assay to verify that treatment of primary glial cells did not influence viability 
substantially(Figure 3).  We also examined whether rolipram differentially influenced viability 
following stimulation of the cells with the inflammatory molecule LPS.  LPS acts through the 
toll-like receptor 4 pathway leading to cellular proliferation and release of inflammatory 
cytokines by immune cells.(Chow et al., 1999).  In these experiments we used LPS as our 
prototypic inflammatory stimulus. We treated the primary glial cells with concentrations of LPS 
ranging from 6.25 ng/mL to 200 ng/mL and performed MTT to examine cell viability(Figure 3).  
There was a drop in viability after LPS treatment at the higher concentrations that was surprising 
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Figure 4: Determination of the viability of mixed glial cells treated 
with rolipram. Mixed glial cells were treated with rolipram at 
increasing concentrations and viability was determined with MTT 
assay.  N=3 cell cultures for each concentration. Kruskal-Wallis(One 
Way ANOVA) analysis demonstrated the difference in viability to be 
significant between the 0.625 μM concentration and the higher 
concentration groups. 
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since 100 ng/mL is 
commonly used to 
activate glial cells in 
other studies(Chen et 
al., 2012).  Rolipram 
treatment alone also 
induced a decrease in 
cell viability at 
concentrations of 5 M 
and higher(Figure 4).   
However, activation of 
glial cells with LPS, 
followed by rolipram 
treatment showed cell loss only at the highest concentration(20 M) while the lowest 
concentrations(0.625M) showed some evidence of proliferation. The combination of 100 
ng/mL of LPS with 5 M rolipram had viability measurements close to 100% and this indicated 
that rolipram was perhaps suppressing the proliferation seen at the lower concentrations.   Based 
on this data, we chose the combination of 100 ng/mL of LPS with 5 M rolipram for our 
metabolomic studies. 
 In order to identify potential anti-inflammatory pathways activated by rolipram 
treatment, we performed a global metabolomic screen of rolipram-treated versus vehicle-control 
THP-1 cells and glial cells.   THP-1 cells would serve as our model of peripheral macrophages 
while testing primary glial cultures would allow us to determine any CNS-specific effects.  We 
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Figure 5: Determination of the viability of mixed glial cells treated 
with rolipram at constant LPs concentration(100ng/mL).  Mixed glial 
cells were treated with LPS at a constant concentration and rolipram 
at increasing concentrations and viability was determined with MTT 
assay.  N=3 cell cultures for each concentration. Kruskal-Wallis(One 
Way ANOVA) analysis demonstrated the difference in viability to be 
significant between the 0.625 μM concentration group and the 2.5, 5, 
and 20 μM concentration groups. 
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performed HILIC-MS on THP-1 
cells treated with rolipram or 
vehicle(DMSO) followed by 
principal component 
analysis(PCA) to identify global 
perturbations in metabolism 
induced by this drug.  PCA 
showed significant separation of 
the feature detection profiles 
between the two groups(Figure 6).   
The results of this test indicate that 
metabolic 
perturbations 
may play a role 
in cellular 
responses to 
rolipram.  In 
fact, we 
detected 
approximately 
818 features 
that were significantly upregulated or downregulated by rolipram treatment in the THP-1 cells 
out of 8094 detected features(p < 0.05, Table 1). Of these changes, we could positively identify 
Figure 6: Principal Component Analysis(PCA) 
comparing rolipram-treated cells (blue) versus 
vehicle controls (red).  Separation of the two groups 
is observed after PCA indicating that rolipram 
induced alterations in the metabolome of THP-1 
cells. 
 
Table 2: A summary of feature and metabolite identification for THP-1 
trial 2.  
 
Table 2: A summary of feature and metabolite identification for THP-1 
trial 2.  
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18 metabolites with fold changes greater than or less than 2 and -2 as well as a set of metabolites 
that were only in one cell population(either control or rolipram-treated with infinity fold change).  
Based on the first trial with THP-1 cells, we performed a second experiment in order to 
determine whether the metabolic changes observed were reproducible.  In this second 
experiment we identified  6777 features in THP-1 cells by HILIC-MS(Table 3). Of those 
detected peaks, statistical analysis identified approximately 524 peaks that were significantly 
altered by rolipram treatment compared with vehicle-control cells.  HMDB searches identified 
approximately 44 metabolites, which were confirmed by matching MS/MS fragmentation data to 
database standards(Table 4).  
We next investigated pathways that were affected by this anti-inflammatory compound.  
The bioinformatics software, Metabolyzer, was used to make putative identifications based on 
m/z values obtained in the two replicate profiling experiments.  These identifications were used 
to create pathway 
maps for related 
metabolites. 
Arginine and 
proline metabolism 
yielded the 
greatest number of 
dysregulated 
metabolites by 
putative 
identification with 
Figure 7: Pathway analysis on putative identifications, matched by 
Kegg ID using Metabolyzer, after inputting retention time and mass to 
charge ratios.  
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smaller numbers of metabolites identified in arachidonic acid metabolism, chemical 
carcinogenesis, and serotonergic synapse response(Figure 7).  
We sought to validate our pathway analysis by confirming the metabolite identifications 
performed by Metabolyzer.  Metabolite identification involves searching publicly available 
databases for matches based on m/z values.  These matches are then confirmed by comparing 
fragmentation patterns 
obtained 
experimentally to 
those obtained with 
standards.  We 
focused on the 
metabolites contained 
in the Human 
Metabolome 
Database(HMDB) and 
National Institue for 
Standards and 
Technology(NIST) to 
provide putative 
identifications since this 
database contains a 
relatively 
comprehensive catalog 
Table 3: Metabolites altered by rolipram treatment in THP-1 
cells. 
Table 4: Identified metabolites regulated by THP-1 treatment 
replicate. 
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of mammalian metabolites(Wishart et al., 2007).   These searches identified approximately 20 
metabolites that were confirmed by matching MS/MS fragmentation patterns to database 
standards(Table 2).   Metabolites that were xenobiotic or plant-derived were excluded. Positively 
identified metabolites found in the human metabolome are listed in Tables 3 and 4 alongside 
their respective p-values and fold changes.  
In the first experiment examining rolipram-treated THP-1 cells, 3'-hydroxy-gamma-
tocotrienol and  4-alpha-carboxy-5alpha-cholesta-8-en-3beta-ol were found to be upregulated but 
identified only putatively, while adenosine was found to be downregulated and positively 
identified by spectra matching. 13'-hydroxy-gamma-tocotrienol is a vitamin E derivative and 
4alpha-carboxy-5alpha-cholesta-8-en-3beta-ol functions as an intermediate in cholesterol 
biosynthesis.  Additionally, 2-Pyrrolidone-5-carboxylic acid, a metabolite identified as an amino 
acid derivative that is a component of glutamine/glutamate metabolism was only present in the 
rolipram treated group and positively identified by MS/MS matching. 
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Several metabolites increased by rolipram treatment in the second trial were amino acid 
or amino acid derivatives, including arginine and the osmolyte betaine(Figure 8 and Table 4).  In 
addition, metabolites involved in the -
oxidation of fatty acids and branched chain 
amino acids, carnitine, valerylcarnitine, 
and butyrylcarnitine are significantly 
increased in THP-1 cells after incubation 
with rolipram.  Finally, we observed 
alterations in the nucleoside, cytidine, 
which increased upon rolipram treatment.  
We compared both trials to 
identify metabolites that are shared 
among both sample sets in order to determine the reproducibility of the metabolite changes. L-
arginine was identified in both sets of experiments; however, it did not make the p-value cutoff 
in the first experiment.  
Vitamin E and cholesterol both play a role in membrane biology; therefore, we used 
shotgun lipidomics to determine whether rolipram might mediate changes in lipid metabolism 
that could influence proliferation or inflammatory responses.  
Figure 8: The osmolyte betaine is increased 
by rolipram treatment. Box and whisker plot 
of betaine from the global profiling 
experiment.  N= 6 were analyzed after 24 
hours of treatment. 
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Shotgun lipidomics was used to profile multiple lipid classes obtained after the 
Bligh-Dyer extraction and a number of lipid classes were found to be dysregulated (Figure 
9). Specific classes upregulated in the experiment were phosphatidylcholines (PC), 
phosphoglycerols(PG), and phosphatidylserines(PS) In contrast, phosphatidic acid(PA) was 
downregulated in the treatment 
group.  
Our metabolomic data 
indicate that rolipram could 
induce alterations in a 
macrophage cell line; however, 
microglial cells are also a 
significant component of the 
innate immune response in the 
CNS.  Although these cells 
display many phenotypic 
similarities to macrophages, 
they also are thought to have a 
unique response to inflammatory stimuli such as differential upregulation of immune 
markers like MHC(Xu, Ling, 1994).  To identify microglial-specific responses to rolipram, 
we cultured primary mouse microglia, treated them with rolipram for 24 hours, and 
performed global metabolomic profiling followed by bioinformatics analysis with the 
Elements program. 
Figure 7: Shotgun lipidomic profiling of THP-1 cells.  
THP-1 cultures were treated with rolipram (5 M) or 
DMSO vehicle for 24 hours followed by lipid extraction. 
Lipids were detected by an MSall method based on accurate 
mass and fragmentation data.  Lipid Classes were graphed 
by ratio of intensity in treatment vs control group, and 
each class was graphed only in the mode (positive or 
negative) in which it was shown to ionize best in.  N= 6 
cultures examined for each treatment condition.  
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We identified 6946 features in the microglia cells by HILIC-MS.  Of those detected 
peaks, statistical analysis identified approximately 322 peaks that were significantly altered by 
rolipram treatment compared with vehicle control cells(Table 5).  Those m/z values were 
matched to metabolites in the Human Metabolome Database(HMDB) to provide putative 
identifications.  No positive identifications were matched by spectra, but putatively identified 
metabolites found in the human metabolome are listed in Table 6, listed alongside their 
respective p-values and 
fold changes.  
S-(3-
Methylbutanoyl)-
dihydrolipoamide-E is an 
intermediate in valine, 
leucine, and isoleucine 
degradation. 11 beta,18,21-
Trihydroxypregn-4-ene-
3,20-dione(18-
Hydroxycorticosterone) is a steroid of the 21-hydroxysteroid class. Both these metabolites were 
significantly downregulated by rolipram treatment, but their identifications were only putative, 
as no spectra could be matched in a database. Our previous results indicated that rolipram 
treatment perturbed multiple classes of lipids in THP-1 cells.  We sought to determine if 
microglial cells also altered their lipid profile after incubation with rolipram. We found several 
classes of lipids differentially regulated by rolipram, including sphingomyelins(SM,) 
phosphatidylserines(PS,) diacylglycerols(DAG,) phopsphatidylglycerols(PG,) ceramides(Cer,) 
Table 5: Metabolic perturbations induced by rolipram in 
primary microglial cell cultures  
Table 6: A chart displaying all putatively identified 
endogenous metabolites for microglia trial 1 that are found in 
the human metabolome, alongside fold change and p-value.  
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phosphatidlycholines(PC,) and 
phosphatidylserines(PS) For most of 
the lipid classes rolipram induced 
upregulation; however, Cer and PE 
species were downregulated. Of note, 
PS were found to be higher in the 
rolipram-treated versus control 
groups in both the microglial and 
THP-1 groups, showing an intensity 
ratio of 1.83 and 4.48 in THP-1 and 
microglia trials, respectively(Figures 
7,9).  
Discussion 
Rolipram is the prototypic PDE-4 inhibitor and treatment of cells with this compound 
leads to increases in cAMP, a pleiotropic signaling molecule.  It is likely that the anti-
inflammatory effects of this drug could result from the activation or suppression of multiple 
signaling pathways; therefore, we used global metabolite profiling to identify biochemical 
alterations induced by this drug.  In order to capture metabolite alterations induced by rolipram, 
we first had to determine a concentration range of the drug that would maintain cell viability in 
the presence and absence of inflammatory mediators like LPS.  Our MTT assays indicated that 
rolipram had some influence on viability at high concentrations. Though no other studies could 
be found investigating the effect of rolipram on macrophage viability, previous studies have 
tested cell viability after 24 hours of rolipram treatment.  Treatment of mixed glial cells with 
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Figure 9:  Shotgun lipidomic profiling of microglial 
cells. Microglia1 cultures were treated with rolipram (5 
M) or DMSO vehicle for 24 hours followed by lipid 
extraction. Lipids were detected by an MSall method based 
on accurate mass and fragmentation data.  Lipid Classes 
were graphed as a ratio intensity between treatment and 
control groups, and each class was graphed only in the 
mode (positive or negative) in which it was shown to 
ionize best in. N= 6 cultures examined for each 
treatment condition. 
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concentrations ranging from 10–7–10-3 M did not have any effect on cell viability(Leseca-
Espinose et al., 2003). This somewhat conflicts with our findings; however, these differential 
responses may be due to cell phenotype. 
Since monocytic cells are one target for rolipram treatment, we examined the metabolic 
response of macrophage cell line, THP-1, to this drug.  PCA analysis indicates that rolipram 
treatment perturbed global metabolism as seen by the separation of treated versus control groups 
on the plot.  We then identified the metabolic pathways that contributed to these differences.  
Overall, 818 features were significantly changed by treatment, but we could only positively 
identify 20 metabolites based on accurate mass and fragmentation data.  The other features 
detected by the mass spectrometry could be true unknowns, metabolites not contained in Metlin 
or HMBD, or metabolites that did not have sufficient fragmentation data to identify. Pathway 
analysis that identified metabolites based on accurate mass suggested several metabolic 
pathways targeted by rolipram. Chief among these was arginine and proline metabolism.  
Arginine was also positively identified as being dysregulated in both sets of THP-1 trials. 
Arginine is one of the primary reactants in NO synthesis, and thus its dysregulation may indicate 
that rolipram not only suppresses cytokine signaling leading to reduced NO production, but may 
also alter the precursors to NO synthesis.  Future directions for the project include targeted 
metabolomics to quantify levels of arginine as well as citrulline and other urea cycle 
intermediates. 
In THP-1 cells, betaine was upregulated with a Log2 fold change of 3.09, which is not 
only significant but of considerable interest to this project. Betaine has been previously 
characterized as an osmolyte and is able to inhibit NO release by LPS-activated microglia 
through an unknown mechanism(Amiraslani et al., 2012).  While this compound may influence 
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NO production directly, betaine is also involved in the regeneration of homocysteine to 
methionine.  Homocysteine is implicated in promoting an NO-secreting M1 phenotype in 
macrophages(Winchester et al., 2015). Therefore, upregulation of betaine may directly influence 
the activity of NO synthase or alternatively prevent activation of this enzyme by decreasing 
levels of homocysteine through its regeneration to methionine.   
We identified fewer numbers of metabolites in microglial cells due to the limited amount 
of MS/MS spectrum collected on the primary cells, and both of our identifications were only 
putative, since there were no spectra to match to in databases for both putative identifications.  
However, matches were obtained for two metabolites, which could possibly later be confirmed 
by matching to standards. 18-Hydroxycorticosterone and S-(3-Methylbutanoyl)-
dihydrolipoamide-E. 18-hydroxycorticosterone is an intermediate in aldosterone synthesis, which 
is mainly performed by the adrenal gland.  Aldosterone can have pro-inflammatory effects; 
however, it is unclear whether this metabolite may be used in another pathway in microglial 
cells(Gilbert, Brown, 2014).  Increases in S-(3-Methylbutanoyl)-dihydrolipoamide-E has been 
previously linked with the development of sepsis(Su et al., 2014).  It remains to be determined 
whether a decrease in this metabolite in microglial cells is associated with a reduction in 
inflammatory responses.  
Shotgun lipidomics produced varying results by trial, but several lipid classes were 
upregulated in rolipram-treated THP-1 cells compared to controls.  Phosphatidylserines(PS) were 
found to be upregulated in rolipram-treatment groups. Interestingly, PS  has been shown to be an 
activator of the rolipram-sensitive PDE-4(Nemoz et al., 1997). It may be that the upregulation of 
PS is an attempt to overcome the rolipram-induced inhibition of this enzyme.  Ceramide species 
also show increases after rolipram treatment in microglial cells. Increases in ceramide levels in 
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microglia occur after LPS treatment(Akundi et al., 2005). It has been shown that upregulation of 
certain ceramides(C2,C8) catalyzes anti-inflammatory effects on LPS-activated mouse 
microglial cells, which include inhibition of NO synthase and the inhibition of the release of 
other pro-inflammatory cytokines(Jung et al., 2013). This result indicates that rolipram has some 
potential to influence levels of these lipids during inflammation.  While multiple lipid species 
change, there appears to be some specificity in lipid alterations.  PC and PG species increase 
while DAG and MAG species do not change.  How this influences cell function remains to be 
determined.  It has been previously shown that inhibition of cAMP breakdown upregulates other 
activators of PDE-4, such as PA in lymphocytes(Nemoz et al., 1997). However, upregulation of 
PA was not seen in this experiment, potentially due differences in cell responses to this 
drug(macrophages versus lymphocytes). This could be an area of future investigation.  
Our metabolomic studies have identified several putative metabolic pathways that 
promote the anti-inflammatory function. The inhibition of NO release from macrophages by 
rolipram has been shown to result from inhibition of cAMP breakdown and reduced transcription 
of NO synthase(Beshay et al., 2001).  Our results suggest that rolipram might also influence the 
availability of amino acid precursors such as arginine used to synthesize NO.  Additionally, we 
saw a decrease in metabolites associated with inflammatory responses, including branched chain 
amino acid derivatives and lipids such as ceramides.  This study highlights the power of 
metabolomics to identify pathways important for drug action. Future work will focus on 
quantifying metabolite changes as well as investigating the downstream effects of these 
metabolite alterations.  
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Appendix 
Supplemental Figures 
 
 
Supplemental Figure 1- MS/MS spectra match for metabolite identification.  The workflow for 
metabolite identification involves matching m/z values detected in the mass spectrometry with 
standards deposited in the Human Metabolome Database.  Metabolite identifications that match 
the experimental m/z value are subsequently validated by matching MS/MS patterns with the 
standards.   
Tumor Necrosis Factor-Alpha ELISA 
 
Supplemental Figure 2- TNF release from glial cultures in response to inflammatory mediators.  
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We sought to determine whether rolipram treatment could alter the release of TNF from glial 
cells in order to confirm that our drug treatment was sufficient to inhibit cAMP breakdown.  In 
order to test the TNF ELISA kit we first examined TNF release after stimulation of the cells with 
known inflammatory molecules LPS and the lipid dimethylsphingosine (DMS).  We treated 
mixed glial cultures with LPS and DMS in the presence or absence of the GPCR signaling 
inhibitor pertussis toxin.  Both LPS and DMS induced TNF release compared to vehicle control, 
consistant with the roles of these inflammatory mediators.  However, when cells were treated 
with LPS or DMS plus pertussis toxin, TNF release was maintained.  Additional DMS + 
pertussis toxin increased TNF release.  These results indicate that TNF measurements by ELISA 
would be sufficient to detect inflammatory activation.  Due to time limitations, I was unable to 
test rolipram-treated cultures.  
 
Safety 
All procedures were conducted under the supervision of Dr. Shriver or one of the several 
graduate students in the laboratory workspace- at least one of these persons was present any time 
work was being conducted to advise on proper safety and experimental procedure. Nitrile gloves 
were worn at all times in the laboratory. Lab aprons, and protective eye and face-wear were worn 
when preparing and handling paraformaldehyde. DMSO and other organic solutions were 
disposed of in the properly marked waste containers.  Biohazard materials such as pipette tips, 
flasks, and plates were disposed of in the properly marked biohazard waste disposal containers. 
Biohazard liquids were properly neutralized, with application of bleach or ethanol, before 
disposed of.  
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